CVS Health’s nearly US$70 billion acquisition of health insurer Aetna was given final approval by a Federal judge after a condition set by the Justice Department was achieved.
The merger was allowed on condition Aetna sell its Medicare prescription drug plan business to WellCare Health Plans and both deals have already closed.
US District Judge Richard Leon had questioned whether the settlement did enough to protect competition and consumers in health-care markets.
Judge Leon said on Wednesday, September 4, that the health care markets at issue in the case “are not only very competitive today, but are likely to remain so post-merger.” The settlement “is well within the reaches of the public interest,” the judge concluded, according to Dow Jones.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI